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Background/Purpose: To evaluate the effect of intravitreal bevacizumab on subretinal ﬂuid absorption in
patients with chronic central serous chorioretinopathy (CSCR).
Materials and methods: This was a retrospective case series study. Patients with CSCR symptoms for > 3
months and who received intravitreal injection of bevacizumab were included. Ocular examinations
were carried out at baseline and every follow-up visit, including visual acuity, fundus examination, and
optic coherence tomography.
Results: Twelve eyes in 12 patients were included in this study. One month after injection, three of the 12
patients who had increased central macular thickness were considered nonresponders. Nine of the 12
patients who had decreased central macular thickness were considered to have responded to intravitreal
bevacizumab injection. The response rate was 75%. In the response group, the mean central macular
thickness signiﬁcantly decreased, from 306.7  77.8 mm to 204.3  59.3 mm (p ¼ 0.001) at 1 month. The
mean Logarithm of the Minimum Angle of Resolution (logMAR) visual acuity was signiﬁcantly improved
from 0.72  0.35 to 0.50  0.28 (p ¼ 0.008). Six of these nine patients had stable conditions lasting > 6
months. Three of them had recurrence.
Conclusion: Intravitreal bevacizumab injections improved subretinal ﬂuid absorption in some patients
with CSCR. It could be an alternative therapy for patients with CSCR, especially when they are not
suitable for other treatments.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Central serous chorioretinopathy (CSCR), also called central se-
rous retinopathy (CSR), is characterized by the development of a
well-circumscribed, serous neurosensory detachment at the pos-
terior pole of the retina, resulting from idiopathic leakage at the
level of the retinal pigment epithelium (RPE). In the majority of
patients, CSCR is a self-limited disease with good visual prognosis.
However, retinal pigment epithelial detachment or subretinal ﬂuid
(SRF) persists in some cases with chronic CSCR, which can cause
RPE atrophy and photoreceptor degeneration, resulting in irre-
versible functional and anatomical damage.1e3 Focal laser photo-
coagulation and photodynamic therapy (PDT) are the most
commonly used treatments for chronic CSCR nowadays, althoughlogy, Kaohsiung Chang Gung
of Medicine, 123 Dapi Road,
.
e Ophthalmologic Society of Taiwthey still have some limitations of application. Recently, intravitreal
bevacizumab injection has shown potential beneﬁts in the treat-
ment of CSCR.4e8 In this study, we investigated the effect of intra-
vitreal bevacizumab injection for patients with chronic CSCR.
2. Materials and methods
This was a retrospective study including patients diagnosed
with CSCR who received intravitreal bevacizumab injection from
February 2008 to September 2011 at Kaohsiung Chang Gung Me-
morial Hospital. Patients who had symptoms of CSCR for > 3
months, diagnosed with chronic CSCR, were included and their
charts were reviewed. Patients with uncertain diagnosis, aged> 55
years, with symptom duration <3 months, or who received other
treatments at the same time were excluded. The patients who
underwent other treatments <6 months prior to the intravitreal
injection were also excluded. All 12 patients received off-label
intravitreal injection of bevacizumab. The off-label use of the
drug and the potential risks and beneﬁts were extensively dis-
cussed with all of the patients. Informed consent was obtainedan. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Changes in mean central retinal thickness (mm) of eyes with time after
treatment with intravitreal bevacizumab for chronic chronic central serous chorior-
etinopathy in the response group. *Represents signiﬁcant difference in comparison to
pre-intravitreal injection (IVI) of bevacizumab (p < 0.05).
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Board of Chang Gung Memorial Hospital approved the study.
Every patient underwent complete clinical assessments,
including visual acuity measurement in Snellen units, fundus ex-
amination, ﬂuorescein angiography, and optic coherence tomog-
raphy (OCT) at baseline. OCT images were obtained from each
affected eye after pupil dilation. Central macular thickness (CMT)
was obtained using the macular thickness map for our calculations.
All the injectionswere performed in anoperating roomand all the
eyes were prepared using a standard procedure, including disinfec-
tion by 5% povidoneeiodine, aseptic procedure, and using a specu-
lum to stabilize the eyelid. Intravitreous injection of bevacizumab by
a 27-gauge needle was performed 3e3.5 mm away from the limbus,
and the dosage of bevacizumab ranged from 1.25 mg (0.05 mL) to
2.5 mg (0.1 mL), according to the physicians’ preference. Tobradex
(tobramycin and dexamethasone) suspension was used after injec-
tion of bevacizumab. Patients were followed up at 1 month, 3
months, and every 3 months thereafter. Visual acuity, fundus ex-
amination, and OCT were performed at every follow-up visit.
SPSS Statistics (version 10; SPSS Inc., Chicago, IL, USA) was used
for statistical analysis. The change of CMT and visual acuity
(Logarithm of the Minimum Angle of Resolution (logMAR units))
were calculated using a paired t test. A p value <0.05 was consid-
ered to be statistically signiﬁcant.3. Results
Twelve eyes in 12 patients were included in this study (Table 1).
The mean age of the patients was 46.8  5.7 years (range: 33e55
years). There were eight men and four women. The mean baseline
CMT by OCT was 300.0  68.9 mm (range: 234e452 mm). The mean
logMAR visual acuity prior to treatment was 0.60  0.37. According
to the CMT at 1 month after injection, the 12 patients were divided
into two groups: the nonresponse group (Patients 1e3) and the
response group (Patients 4e12).
In the nonresponse group, CMT signiﬁcantly increased from
280.3  33.0 mm to 327.3  35.2 mm (p ¼ 0.02). This situation has
not been reported in previous studies. All three patients in the
nonresponse group received further treatment, including trans-
pupillary thermotherapy, repeat intravitreal bevacizumab injec-
tion, or other treatment.
In the response group, the mean CMT decreased from
306.7  77.8 mm to 204.3  59.3 mm (p ¼ 0.001, Fig. 1). The mean
logMAR visual acuitywas signiﬁcantly improved, from 0.72 0.35 to
0.50 0.28 (p¼ 0.008, Fig. 2). Theninepatients in the response groupTable 1
Characteristics, visual acuity, and central macular thickness prior to and after intravitreo
Patient
no.
Sex Age (y) Duration
(mo)
Pre-IVI VA
(logMAR)
Pre-IVI
CMT
Dose
(mL)
1M
(log
1 F 49 19 0.30 312 0.08 0.70
2 M 36 >12 0.30 246 0.1 0.40
3 M 51 12 0.15 282 0.05 0.05
4 M 53 6 0.30 250 0.1 0.30
5 M 42 4 0.70 391 0.05 0.30
6 M 55 >12 0.40 237 0.1 0.30
7 M 49 6 1.00 318 0.1 0.70
8 M 49 24 0.30 347 0.05 0.22
9 F 45 15 0.52 236 0.05 0.30
10 M 43 4 1.00 234 0.05 0.70
11 F 40 3 1.22 295 0.1 0.70
12 F 48 6 1.00 452 0.05 1.00
1M ¼ 1 month; 3M ¼ 3 months; CMT ¼ central macular thickness; F ¼ female; IVIB ¼ int
Resolution; M ¼ male; PDT ¼ photodynamic therapy; TTT ¼Transpupillary Thermal The
a Performed after 1 month follow-up.
b Performed after 3 months follow-up.received further follow-up. At 3 months, the mean CMT was
229.6 97.8 mmand themean logMAR visual acuitywas 0.45 0.29.
The changes in mean CMT and logMAR visual acuity are shown in
Figs.1 and 2. At 3months follow-up, Patients 4e9had stable CMTand
visual acuity. In addition, all six patients who had stable CMT at 3
months follow-up had stable conditions that lasted 6 months
(range: 6 months to 2.5 years) with mean logMAR visual acuity of
0.310.18. Patients 10e12 in the response group had a relapse of SRF
at 3months follow-up. Themean CMTof the three patients increased
from 256.0  38.0 mm at 1 month follow-up to 330.0  59.1 mm at 3
months follow-up. Patients 10 and 11 underwent secondary intra-
vitreal bevacizumab injection. CMT decreased at 1 month after the
secondary bevacizumab injection, but increased at 3e6months later,
which was similar to the result of the ﬁrst injection. In other words,
the intravitreal bevacizumab injection seemed to show only short-
term effects in these two patients. Patient 12 received half-dose
PDT as further treatment and had a stable condition for about 1
year. The effects of different doses of bevacizumab were compared.
Sevenpatients received1.25mg (0.05mL) bevacizumab injectionand
ﬁve patients received 2.5 mg (0.1 mL). At 1 month follow-up, there
was no signiﬁcant difference in the decrease in mean CMT
(73.14  94.96 mm vs. 53.40  78.33 mm, p ¼ 0.712).
In summary, out of all 12 patients who received intravitreal
bevacizumab injections, three (25%) did not show improvement inus injection of bevacizumab.
VA
MAR)
1M CMT 3M VA
(logMAR)
3M CMT Further
management
Final VA
(logMAR)
367 0.70 205 Repeat IVIBa 0.10
300 0.52 319 Othersa 0.40
315 0.10 304 TTTa 0.30
232 0.22 247 Observation 0.22
229 e e Observation 0.30
123 0.40 131 Observation 0.40
175 0.52 174 Observation 0.52
199 0 187 Observation 0.00
113 0.52 108 Observation 0.70
222 0.52 262 Repeat IVIBb 0.70
249 0.40 359 Repeat IVIBb 1.00
297 1 369 Half-dose PDTb 0.40
ravitreous injection of bevacizumab; logMAR ¼ Logarithm of the Minimum Angle of
rapy; VA ¼ visual acuity.
Fig. 2. Changes in the mean logMAR visual acuity of eyes with time after treatment
with intravitreal bevacizumab for chronic chronic central serous chorioretinopathy in
the response group. *Represents signiﬁcant difference in comparison to pre-
intravitreal injection (IVI) of bevacizumab (p < 0.05).
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showed only short-term effects in SRF absorption, and they may
need additional injections to maintain the effects. Six patients
(50%) showed long-term effects of SRF absorption, which lasted 6
months.4. Discussion
CSCR is generally considered to be a self-limited disease. The SRF
resolves within 3 months without speciﬁc treatment in most pa-
tients with CSCR, and most of them recover their baseline visual
acuity.9,10 However, early resolution of SRF may have potential
beneﬁts, such as a lower rate of RPE degeneration and better re-
covery of visual acuity.2,11 Therefore, in patients with long-term
CSCR, treatment is recommended. Presently, CSCR is usually
treated by laser photocoagulation or PDT. Photocoagulation is the
most frequently used treatment for CSCR; however, itmaycauseRPE
damage and induce scotoma formation. Therefore, photocoagula-
tion is not suggested when the lesion involves the fovea. Recently,
PDT has been proven to be effective for chronic CSCR, although it is
associatedwith signiﬁcant complications suchas choroidal ischemia
and secondary choroidal neovascularization.12,13 Additionally, the
high cost of PDT is also of concern for patients.
Although the pathogenesis of CSCR is not completely under-
stood, choroidal venous congestion may play a role, as indicated by
indocyanine green angiography.14e16 It might be due to ischemia,
delayed arterial ﬁlling, or venous outﬂow obstruction. Vascular
endothelial growth factor (VEGF) is a potent inducer of vascular
permeability17 and produced by damaged retinal and choroidal
cells after abnormal vascular change or ischemia. The choroidal
vascular hyperpermeability results in excessive tissue hydrostatic
pressure within the choroid and leads to disruption of the RPE
barrier that secondarily destroys the ability of RPE to pump ﬂuid
from the retina to the choroid.18 Therefore, intravitreal injection of
bevacizumab (an antibody that binds all the isoforms of vascular
endothelial growth factor) might be effective for reducing neuro-
sensory detachment.
Previous studies have reported the effect of intravitreal bev-
acizumab injection that showed the complete absorption of SRF at a
rate of 50e100% after intravitreal bevacizumab injection.4e8,19,20 In
our study, nine of the 12 patients (response group) show absorption
of SRF, which fell within the reported spectrum. There were three
cases showing increased SRFafter intravitreal bevacizumab injection
(nonresponse group) in this study; such conditions have not been
previously reported. This ﬁnding suggests that intravitrealbevacizumab injection is not always an effective treatmentmodality
for all patientswith chronic CSCR. In the response group, six patients
showedstableCMTandnomore SRF for6months (range: 6months
to 2.5 years). However, three of the nine patients in the response
grouphada relapse of SRFat 3months follow-up. Recurrenceof CSCR
has been reported in previous studies at a rate of 21.2e66.7%,7,19,20
and a similar recurrence rate was noted in our study. Other studies
have shown that the half-life of bevacizumab in the vitreous ﬂuid is
5.6 days and it remains present in the eye for 4e6 weeks.21e23 CSCR
might recur when the dose of bevacizumab in the vitreous ﬂuid is
decreasing. Two of the three patients with recurrences received
secondary intravitreal bevacizumab injection, and SRFwas absorbed
within 1 month after the secondary injection. However, 3 months
later, recurrences with SRF accumulation was noted again in these
two patients. This ﬁnding suggests that intravitreal bevacizumab
injections provide only short-term effects in SRF absorption in some
cases, even if they are sensitive to the treatment.
There were limitations to this study, including the retrospective
design, short-term follow-up period, and small sample size. There
was no control group to compare the natural course of CSCR, so
some cases in the response group might have undergone sponta-
neous improvement or resolution naturally, which simply coin-
cided with the treatments. Besides, CSCR typically presents in
adults aged 25e50 years. In older patients, this condition can easily
be mistaken for macular degeneration with subretinal neo-
vascularization. Although there were three patients aged > 50
years in our series, all of their ﬂuorescein angiography showed one
or several small pinpoint leaks in the early phase, which enlarged
and developed fuzzy margins. One of them had indocyanine green
angiography to exclude the possibility of age-related macular
degeneration. None of these three cases developed drusen, sub-
retinal hemorrhage, exudate, geographic atrophy, a dirty gray
subretinal membrane, and signs of subretinal neovascularization
during the further 1-year follow-up period. Therefore, for patients
aged > 50 years, indocyanine green angiography should be per-
formed to exclude the possibility of age-related macular degener-
ation or other macular disease. Further larger, randomized, and
well-designed prospective studies with control groups are
needed to determine the long-term treatment beneﬁts and the
safety of intravitreal bevacizumab injection for CSCR.
In conclusion, our study suggests that intravitreal bevacizumab
injection may be an alternative treatment choice for patients with
chronic CSCR, especially in those who are not suitable or indicated
for laser treatment and PDT.References
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